Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 14;16(4):1188-1199.
doi: 10.3390/pediatric16040100.

Enhanced Metabolic Control in a Pediatric Population with Type 1 Diabetes Mellitus Using Hybrid Closed-Loop and Predictive Low-Glucose Suspend Insulin Pump Treatments

Irina Bojoga  1   2 , Sorin Ioacara  1   2 , Elisabeta Malinici  1   2 , Victor Chiper  1   2 , Olivia Georgescu  1   2 , Anca Elena Sirbu  1   2 , Simona Fica  1   2
Affiliations

Enhanced Metabolic Control in a Pediatric Population with Type 1 Diabetes Mellitus Using Hybrid Closed-Loop and Predictive Low-Glucose Suspend Insulin Pump Treatments

Irina Bojoga et al. Pediatr Rep. .

Abstract

Background: Insulin pumps coupled with continuous glucose monitoring sensors use algorithms to analyze real-time blood glucose levels. This allows for the suspension of insulin administration before hypoglycemic thresholds are reached or for adaptive tuning in hybrid closed-loop systems. This longitudinal retrospective study aims to analyze real-world glycemic outcomes in a pediatric population transitioning to such devices.

Methods: We evaluated children with type 1 diabetes mellitus (T1D) admitted to the Pediatric Diabetes Department from a major University Hospital in Bucharest, Romania, who transitioned to hybrid closed-loop or predictive low-glucose suspend system from either non-automated insulin pumps or multiple daily injections. The primary outcome was assessing the change in glycated hemoglobin (HbA1c) after initiating these devices. Secondary outcomes analyzed changes in glucose metrics from the 90 days prior to the baseline and follow-up visit.

Results: 51 children were included (58.8% girls), the mean age was 10.3 ± 3.7 years, and the mean follow-up duration was 13.2 ± 4.5 months. The analyzed parameters, such as HbA1c (6.9 ± 0.7% vs. 6.7 ± 0.6%, p = 0.023), time in range (69.3 ± 11.2% vs. 76 ± 9.9%, p < 0.001), time in tight range (47.4 ± 10.9% vs. 53.7 ± 10.7%, p < 0.001), time below range (5.6 ± 2.9% vs. 3.5 ± 1.9%, p < 0.001), time above range (25 ± 11.2% vs. 20.4 ± 9.4%, p = 0.001), and coefficient of variation (37.9 ± 4.8% vs. 35.6 ± 4.6%, p = 0.001), showed significant improvements.

Conclusions: The application of these sensor-integrated insulin pumps can significantly enhance metabolic control in pediatric populations, minimizing glycemic variations to mitigate complications and enrich the quality of life.

Keywords: automated insulin delivery systems; glycemic control; hybrid closed-loop systems; insulin pump; pediatric diabetes; technological devices; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Gregory G.A., Robinson T.I.G., Linklater S.E., Wang F., Colagiuri S., de Beaufort C., Donaghue K.C., Magliano D.J., Maniam J., Orchard T.J., et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: A modelling study. Lancet Diabetes Endocrinol. 2022;10:741–760. doi: 10.1016/S2213-8587(22)00218-2. - DOI - PubMed
    1. Theofilou P., Vlastos D.D. The Psychological Burden of Families with Diabetic Children: A Literature Review Focusing on Quality of Life and Stress. Children. 2023;10:937. doi: 10.3390/children10060937. - DOI - PMC - PubMed
    1. Zahid M., Dowlatshahi S., Kansara A.H., Sadhu A.R. The Evolution of Diabetes Technology—Options Toward Personalized Care. Endocr. Pract. 2023;29:653–662. doi: 10.1016/j.eprac.2023.04.007. - DOI - PubMed
    1. Kesavadev J., Saboo B., Krishna M.B., Krishnan G. Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. Diabetes Ther. 2020;11:1251–1269. doi: 10.1007/s13300-020-00831-z. - DOI - PMC - PubMed
    1. Medtronic. (21 April 2023). MiniMedTM 780G System. Medtronic Diabetes. [(accessed on 30 June 2024)]. Available online: https://www.medtronicdiabetes.com/products/minimed-780g-insulin-pump-system.

LinkOut - more resources